Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pseudomonas aeruginosa phage PASA16
- Development stage
- Discontinued
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous, Topical
01
Overview
Pseudomonas aeruginosa phage PASA16 is a naturally occurring, lytic bacteriophage belonging to the Myoviridae family (specifically Pbunavirus genus) that specifically targets and lyses Pseudomonas aeruginosa. Originally isolated from a soil sample in Jerusalem by researchers at the Hebrew University of Jerusalem and Hadassah Medical Center, PASA16 has been utilized globally under compassionate use (expanded access) protocols to treat patients with refractory, non-resolving, and multidrug-resistant P. aeruginosa infections, including osteoarticular, foreign-device-associated, and endovascular left ventricular assist device (LVAD) infections. The phage was manufactured and provided pro-bono for clinical use by Adaptive Phage Therapeutics (which merged with BiomX in 2024). However, in 2026, BiomX announced a complete exit from phage therapy development to pivot into the defense sector, leading to the discontinuation of its clinical phage programs and the winding down of Adaptive Phage Therapeutics.
- Other names
- PASA16PASA-16PASA 16PASA16 phagePASA-16 phagePASA 16 phagePa14NP∅PASA16Pa14NPΦPASA16bacteriophage PASA16phage PASA16
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on Pseudomonas aeruginosa phage PASA16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pseudomonas aeruginosa phage PASA16.